Navigation Links
MAQUET Cardiovascular Receives FDA 510(k) Clearance and CE Mark for Its New SENSATION PLUS™ Intra-Aortic Balloon Catheter
Date:9/20/2011

MAHWAH, N.J., Sept. 20, 2011 /PRNewswire/ -- MAQUET Cardiovascular, a leading provider of cardiovascular technologies, announced today that it has received both 510(k) clearance from the U.S. Food & Drug Administration (FDA) and CE mark approval from the British Standards Institution (BSi) for its new SENSATION PLUS™ 50cc 8 Fr. intra-aortic balloon catheter.  The new SENSATION PLUS intra-aortic balloon (IAB) catheter is the first 50cc 8 Fr. IAB catheter to combine fiber optic signal acquisition with greater hemodynamic support compared to a standard 40cc IAB catheter.

"Clinicians have been asking for an IAB that combines all of the benefits of fiber optic technology; faster initiation of therapy, easier patient management and a crisp, clean arterial pressure wave form with increased hemodynamic support," said Deb Joseph, Vice President, Marketing and Clinical Services.  "We believe that the new, state-of-the art SENSATION PLUS™ intra-aortic balloon catheter meets these needs and will enable clinicians to provide patients with improved care."

The new 50cc 8Fr. SENSATION PLUS IAB catheter provides greater patient support, comfort and ease of use than any IAB catheter MAQUET has ever offered. SENSATION PLUS incorporates fiber optic signal acquisition and provides 25 percent more blood volume displacement than standard 40cc IAB catheters, allowing for improved unloading and better augmentation. This new IAB catheter also comes with two Stat Lock® IAB stabilization devices which allow the catheter to be secured to the patient's leg without sutures. This is more comfortable for patients and eliminates the risk of suture needle sticks for clinicians when initiating counterpulsation support.  The new IAB catheter will be available for sale in October.

"SENSATION PLUS underscores MAQUET's commitment to meeting the needs of clinicians treating hemodynamically compromised patients and to improving outcomes," said Christian Keller, President of MAQUET Cardiovascular. "Up to this point, clinicians have had to choose between greater support and the benefits of fiber optic technology. Now they can have both. SENSATION PLUS represents a new standard of care with respect to intra-aortic counterpulsation therapy."

Intra-aortic balloon counterpulsation is an adjunctive therapy that is often used in patients with left ventricular failure and other cardiac conditions. When the IAB inserted into the patient's aorta counterpulsates with the heart, it augments coronary blood flow to increase myocardial oxygen supply and decrease myocardial oxygen demand.

For more information about MAQUET Cardiovascular, please visit http://ca.maquet.com.

INFORMATION ABOUT MAQUET

As a trusted partner for hospitals and clinicians since 1838, Maquet is a global leader in medical systems that advance surgical interventions, cardiovascular procedures and critical care. Maquet develops and designs innovative products and therapeutic applications for the operating room, hybrid OR/cath lab, intensive care unit and patient transport within acute care hospitals, improving outcomes and quality of life for patients.

Cardiovascular specialties include intra-aortic balloon counterpulsation (IABC) therapy for cardiac assist; coronary artery bypass surgery; aortic and peripheral vascular surgery; and extracorporeal circulation.

The Critical Care portfolio includes market-leading intensive care ventilators and anesthesia machines.

Maquet also equips Surgical Workplaces with critical infrastructure such as flexible room design for OR and ICU; OR tables; lights and ceiling supply units; and OR integration for image data management.

Maquet is a subsidiary of the publicly listed Swedish Getinge Group. In 2010, Maquet generated nearly half of the Group’s annual revenue of 2.3 billion Euros. The Getinge Group has more than 12,000 employees worldwide, including around 5,000 Maquet employees in 36 international sales and service organizations, as well as a network of more than 250 sales representatives. For more information please visit www.maquet.com and www.getingegroup.com.

MAQUET – The Gold Standard.


'/>"/>
SOURCE MAQUET Cardiovascular
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MAQUET Cardiovascular Receives Guaranteed Two-Year Sole Source Contract From Novation for Beating Heart Surgical Devices
2. MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices
3. MAQUET Cardiovascular Introduces New VASOSHIELD Pressure Controlling Syringe to Help Preserve Graft Integrity for Coronary Artery Bypass Surgery Patients
4. MAQUET Cardiovascular Launches Advanced VASOVIEW Technology for Endoscopic Vessel Harvesting Procedures in Cardiac Surgery
5. MAQUET Cardiovascular Launches New VASOVIEW 6 PRO Endoscopic Vessel Harvesting System
6. MAQUET Cardiovascular Receives 510(k) Clearance to Market the CARDIOHELP System in U.S.
7. UPDATE - MAQUET Cardiovascular Receives 510(k) Clearance to Market the CARDIOHELP System in U.S.
8. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
9. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
10. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
11. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... and PUNE, India , January ... by Allied Market Research, titled, "Breast Imaging Technologies Market by ... the global breast imaging technologies market size was valued at ... million by 2022, growing at a CAGR of 8.4% from ... Europe together accounted for over three-fourths ...
(Date:1/18/2017)... , Jan. 18, 2017   Regenicin, Inc. ... biotechnology company specializing in the development and commercialization of ... tissues and organs, recently reported the Company,s operating results ... 2017. As the Company described in its ... a year of substantial accomplishments. The Company,s contract laboratory ...
(Date:1/18/2017)... de 2017  Hoy, en el Foro Económico Mundial, ... global para avanzar el acceso a la prevención de ... renta baja y baja-media (LICs y LMICs). ... particularmente en países de renta baja y media, donde ... muertes relacionadas con NCD. El objetivo de Access Accelerated, ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... ... CTMS, which provides a modern CTMS workflow designed to seamlessly integrate and streamline ... been condensed to a single page, maximizing usability and improving efficiency significantly for ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... and staff members in 2017 who are passionate about making a difference in ... 1994 and headquartered in Tampa, UMA, a nonprofit healthcare educational institution, has more ...
(Date:1/19/2017)... ... 2017 , ... For the third year running, Noto Insurance ... surrounding area, is inaugurating a charity event to help raise funds for ... Gehrig's disease or motor neurone disease, is a deadly neurological disorder that affects ...
(Date:1/19/2017)... (PRWEB) , ... January 18, 2017 , ... The CHP ... driving during a rain storm by slowing down and increasing the space between themselves ... 40. Los Angeles based car accident attorney Raymond R. Hassanlou notes that, rain or ...
(Date:1/19/2017)... ... January 19, 2017 , ... "ProParagraph Basics is ... the editing process for all media productions," said Christina Austin - CEO of ... simplistically styled self-animating paragraphs designed for multi-lined text purposes. Choose from presets ...
Breaking Medicine News(10 mins):